Western pharmaceutical companies are in talks with alternative suppliers in response to draft US legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns. The Biosecure Act would prohibit US companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and its sister company WuXi Biologics, which produce active pharmaceutical ingredients (API) for hundreds of US and European drugmakers.
西方製藥公司正與替代供應商進行談判，以應對美國一項立法草案，該草案試圖以國家安全爲由，限制一家重要的中國藥物開發商和製造商。《生物安全法案》(The Biosecure Act)擬禁止接受聯邦撥款的美國公司與四家中國生物技術公司合作，其中包括藥明康德(WuXi AppTec)及其姊妹公司藥明生物(WuXi Biologics)，它們爲數百家美國和歐洲製藥商生產活性藥物成分(API)。
您已閱讀10%（692字），剩餘90%（6416字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。